The diflunisal trial: Update on study drug tolerance and disease progression

J. L. Berk; P. J. Dyck; L. Obici; S. R. Zeldenrust; Y. Sekijima; T. Yamashita; Y. Ando; S. I. Ikeda; P. Gorevic; G. Merlini; J. W. Kelly; M. Skinner; A. B. Bisbee; O. B. Suhr

doi:10.3109/13506129.2011.574354

The diflunisal trial: Update on study drug tolerance and disease progression

J. L. Berk, P. J. Dyck, L. Obici, S. R. Zeldenrust, Y. Sekijima, T. Yamashita, Y. Ando, S. I. Ikeda, P. Gorevic, G. Merlini, J. W. Kelly, M. Skinner, A. B. Bisbee, O. B. Suhr

Neurology

Research output: Contribution to journal › Article

12 Scopus citations

Abstract

Familial amyloidotic polyneuropathy (FAP) is a lethal genetic disorder that affects the peripheral and autonomic nervous systems, heart, gastro-intestinal (GI) tract, and soft tissues. Disease progression is increasingly reported following liver transplantation, the only proven treatment for FAP. Small molecule thyroxine mimetics stabilize transthyretin, inhibiting FAP amyloid fibril formation under stringent in vitro conditions. We report on the progress of an international, randomized placebocontrolled study designed to determine the effect of diflunisal, a thyroxine mimetic, on neurologic disease progression in patients with active FAP. Our experience to date indicates diflunisal is well tolerated by this study cohort and that neurologic disease advances more rapidly in FAP than it does in diabetes mellitus.

Original language	English (US)
Pages (from-to)	196-197
Number of pages	2
Journal	Amyloid
Volume	18
Issue number	SUPPL. 1
DOIs	https://doi.org/10.3109/13506129.2011.574354
State	Published - Jun 1 2011

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.3109/13506129.2011.574354

Fingerprint Dive into the research topics of 'The diflunisal trial: Update on study drug tolerance and disease progression'. Together they form a unique fingerprint.

Cite this

Berk, J. L., Dyck, P. J., Obici, L., Zeldenrust, S. R., Sekijima, Y., Yamashita, T., Ando, Y., Ikeda, S. I., Gorevic, P., Merlini, G., Kelly, J. W., Skinner, M., Bisbee, A. B., & Suhr, O. B. (2011). The diflunisal trial: Update on study drug tolerance and disease progression. Amyloid, 18(SUPPL. 1), 196-197. https://doi.org/10.3109/13506129.2011.574354

The diflunisal trial : Update on study drug tolerance and disease progression. / Berk, J. L.; Dyck, P. J.; Obici, L.; Zeldenrust, S. R.; Sekijima, Y.; Yamashita, T.; Ando, Y.; Ikeda, S. I.; Gorevic, P.; Merlini, G.; Kelly, J. W.; Skinner, M.; Bisbee, A. B.; Suhr, O. B.

In: Amyloid, Vol. 18, No. SUPPL. 1, 01.06.2011, p. 196-197.

Research output: Contribution to journal › Article

@article{a1ac21f52a8a4ef8b0db3dbc1c314172,

title = "The diflunisal trial: Update on study drug tolerance and disease progression",

abstract = "Familial amyloidotic polyneuropathy (FAP) is a lethal genetic disorder that affects the peripheral and autonomic nervous systems, heart, gastro-intestinal (GI) tract, and soft tissues. Disease progression is increasingly reported following liver transplantation, the only proven treatment for FAP. Small molecule thyroxine mimetics stabilize transthyretin, inhibiting FAP amyloid fibril formation under stringent in vitro conditions. We report on the progress of an international, randomized placebocontrolled study designed to determine the effect of diflunisal, a thyroxine mimetic, on neurologic disease progression in patients with active FAP. Our experience to date indicates diflunisal is well tolerated by this study cohort and that neurologic disease advances more rapidly in FAP than it does in diabetes mellitus.",

author = "Berk, {J. L.} and Dyck, {P. J.} and L. Obici and Zeldenrust, {S. R.} and Y. Sekijima and T. Yamashita and Y. Ando and Ikeda, {S. I.} and P. Gorevic and G. Merlini and Kelly, {J. W.} and M. Skinner and Bisbee, {A. B.} and Suhr, {O. B.}",

year = "2011",

month = jun,

day = "1",

doi = "10.3109/13506129.2011.574354",

language = "English (US)",

volume = "18",

pages = "196--197",

journal = "Amyloid",

issn = "1350-6129",

publisher = "Informa Healthcare",

number = "SUPPL. 1",

}

TY - JOUR

T1 - The diflunisal trial

T2 - Update on study drug tolerance and disease progression

AU - Berk, J. L.

AU - Dyck, P. J.

AU - Obici, L.

AU - Zeldenrust, S. R.

AU - Sekijima, Y.

AU - Yamashita, T.

AU - Ando, Y.

AU - Ikeda, S. I.

AU - Gorevic, P.

AU - Merlini, G.

AU - Kelly, J. W.

AU - Skinner, M.

AU - Bisbee, A. B.

AU - Suhr, O. B.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Familial amyloidotic polyneuropathy (FAP) is a lethal genetic disorder that affects the peripheral and autonomic nervous systems, heart, gastro-intestinal (GI) tract, and soft tissues. Disease progression is increasingly reported following liver transplantation, the only proven treatment for FAP. Small molecule thyroxine mimetics stabilize transthyretin, inhibiting FAP amyloid fibril formation under stringent in vitro conditions. We report on the progress of an international, randomized placebocontrolled study designed to determine the effect of diflunisal, a thyroxine mimetic, on neurologic disease progression in patients with active FAP. Our experience to date indicates diflunisal is well tolerated by this study cohort and that neurologic disease advances more rapidly in FAP than it does in diabetes mellitus.

AB - Familial amyloidotic polyneuropathy (FAP) is a lethal genetic disorder that affects the peripheral and autonomic nervous systems, heart, gastro-intestinal (GI) tract, and soft tissues. Disease progression is increasingly reported following liver transplantation, the only proven treatment for FAP. Small molecule thyroxine mimetics stabilize transthyretin, inhibiting FAP amyloid fibril formation under stringent in vitro conditions. We report on the progress of an international, randomized placebocontrolled study designed to determine the effect of diflunisal, a thyroxine mimetic, on neurologic disease progression in patients with active FAP. Our experience to date indicates diflunisal is well tolerated by this study cohort and that neurologic disease advances more rapidly in FAP than it does in diabetes mellitus.

UR - http://www.scopus.com/inward/record.url?scp=79959948406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959948406&partnerID=8YFLogxK

U2 - 10.3109/13506129.2011.574354

DO - 10.3109/13506129.2011.574354

M3 - Article

AN - SCOPUS:79959948406

VL - 18

SP - 196

EP - 197

JO - Amyloid

JF - Amyloid

SN - 1350-6129

IS - SUPPL. 1

ER -